The board of directors of SSY Group Limited announced that the Group's Isoprenaline hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market, being the second of such approval in the PRC.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.93 HKD | +0.41% | +3.35% | 0.00% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
0.00% | 1.87B | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- 2005 Stock
- News SSY Group Limited
- SSY Group Limited Announces Update on Product Development